Skip to main content
Download PDF

Bacteria-based multiplex system eradicates recurrent infections with drug-resistant bacteria via photothermal killing and protective immunity elicitation

Biomaterials Research volume 27, Article number: 27 (2023) Cite this article

Abstract

Background

The high mortality associated with drug-resistant bacterial infections is an intractable clinical problem resulting from the low susceptibility of these bacteria to antibiotics and the high incidence of recurrent infections.

Methods

Herein, a photosynthetic bacteria-based multiplex system (Rp@Al) composed of natural Rhodopseudomonas palustris (Rp) and Food and Drug Administration-approved aluminum (Al) adjuvant, was developed to combat drug-resistant bacterial infections and prevent their recurrence. We examined its photothermal performance and in vitro and in vivo antibacterial ability; revealed its protective immunomodulatory effect; verified its preventative effect on recurrent infections; and demonstrated the system’s safety.

Results

Rp@Al exhibits excellent photothermal properties with an effective elimination of methicillin-resistant Staphylococcus aureus (MRSA). In addition, Rp@Al enhances dendritic cell activation and further triggers a T helper 1 (TH1)/TH2 immune response, resulting in pathogen-specific immunological memory against recurrent MRSA infection. Upon second infection, Rp@Al-treated mice show significantly lower bacterial burden, faster abscess recovery, and higher survival under near-lethal infection doses than control mice.

Conclusions

This innovative multiplex system, with superior photothermal and immunomodulatory effects, presents great potential for the treatment and prevention of drug-resistant bacterial infections.

Graphical Abstract

Background

In clinics, antibiotics are the preferred line of treatment for bacterial infections. However, their misuse has resulted in the emergence and rapid increase of multidrug-resistant pathogens [1,2,3,4]. A comprehensive study of 204 countries and territories estimated that there were 4.95 million deaths associated with antimicrobial resistance (AMR), which has become the third leading cause of death worldwide [5]. Furthermore, a review on AMR, commissioned by the UK government, reported that AMR-related deaths will exceed 10 million annually by 2050, surpassing cancer-related deaths [6]. The high mortality associated with drug-resistant bacterial infections is ascribed not only to the low susceptibility of these bacteria to antibiotics, but also to the high incidence of recurrent infections [7, 8]. Methicillin-resistant Staphylococcus aureus (MRSA), with a high risk of recurrence, is one of the most common drug-resistant bacteria in bacteremia, endocarditis, skin and soft tissue infections, bone and joint infections, and hospital-acquired infections [9]. Therefore, it is imperative to develop non-antibiotic therapies that integrate treatment and prevention against drug-resistant bacteria and their recurrent infections.

Bacteria-mediated therapies have attracted remarkable attention in recent years [10,11,12,13,14,15]. Bacteria possess considerable tumor-targeting ability because they can infiltrate tumors and surviving in the tumor hypoxic microenvironment, as well as immunoregulatory capacity owing to their immunogenicity [16,17,18,19]. Therefore, a series of bacteria-based strategies (including Escherichia, Salmonella, and Listeria) have been developed for cancer therapies [20,21,22,23,24]. In addition, probiotics (such as bifidobacteria and lactobacilli) with anti-inflammatory and immunomodulatory abilities are employed in the treatment of various gastrointestinal diseases, such as inflammatory bowel disease, acute pancreatitis, and Helicobacter pylori infections [25, 26]. Photosynthetic bacteria (PSB), the earliest photoautotrophic microorganisms, have been widely used as aquaculture feed because of their high nutrient content (including proteins, amino acids, vitamins, and bioactive substances) [27,28,29]. PSB, which have a primitive photoenergy synthesis system, carry out photosynthesis mainly through their bacteriochlorophyll (BChl), which converts sunlight into energy needed for metabolism. Importantly, BChl absorbs near-infrared (NIR) light with maximum absorption peaks around 805 and 865 nm, suggesting that PSB may be an innovative candidate for novel photothermal reagents [30,31,32]. Therefore, we believe that PSB-based photothermal therapy with less invasiveness and a lower risk of drug resistance has great potential against infections by drug-resistant bacteria, which has not been reported to date [33,34,35,36].

Host immunomodulatory therapies, which exploit the host-dependent natural mechanisms to activate or strengthen protective antimicrobial immunity, are a promising strategy for the prevention of drug-resistant bacterial infections [37,38,39,40,41,42,43]. A series of immunomodulators have been proposed for drug-resistant bacterial infections, including agonists that target natural immune pattern recognition receptors [PRRs; such as Toll-like receptors (TLRs) and NOD-like receptors (NLRs)] and immunomodulatory host defense peptides (also called antimicrobial peptides) [37, 44, 45]. Microbial signature components and endogenous damage-associated molecular patterns interact with PRRs, triggering the activation of mitogen-activated protein kinase and nuclear factor-κB signaling pathways, thereby activating innate immunity, and promoting the induction of antimicrobial effector functions [46, 47]. The activation of innate immunity is critical for the induction of adaptive immunity, which facilitates protective antimicrobial immunity. Agonists of TLRs and NLRs have been demonstrated to be safe and effective vaccine adjuvants, and the potential of immunomodulatory strategies against bacterial infections by targeting PRRs have also been explored [48, 49]. Food and Drug Administration-approved aluminum (Al) adjuvant, the most common NLRs agonist, has been reported to preferentially prime CD4+ T cells, which further activate B cells, thereby initiating an adaptive immunity response [50, 51]. Thus, immunomodulatory therapy is a potential approach to prevent recurrent infection with drug-resistant bacteria.

To achieve this, we integrated immunomodulatory therapy with bacteria-mediated photothermal therapy to achieve the following: i) develop a PSB-based multiplex system for treatment and prevention of drug-resistant bacterial infections; ii) demonstrate the photothermal killing effect of the system on drug-resistant bacteria; and iii) assess the immunomodulatory effect of the system in preventing recurrent infection with drug-resistant bacteria. We expect this study to provide guidelines for the design of bacteria-mediated antimicrobial systems and shed light on the development of “smart” systems that integrate bacterial treatment and prevention methodologies for clinical application in other AMR-related diseases.

Methods

Materials

Alhydrogel® adjuvant 2% was purchased from InvivoGen (San Diego, CA, USA). Brain Heart Infusion (BHI) Broth and BHI Agar were purchased from Qingdao Hope Bio-Technology Co., Ltd. (Qingdao, China). Crystal violet was purchased from Sangon Biotech Co., Ltd. (Shanghai, China). Dichloro-dihydro-fluorescein diacetate (DCFH-DA) was purchased from Beyotime Biotechnology (Shanghai, China). Masson’s trichrome staining kit was purchased from Beijing Solarbio Science & Technology Co., Ltd. (Beijing, China). Red blood cell lysis buffer and 4′,6-diamidino-2-phenylindole were purchased from Beyotime Biotechnology (Shanghai, China). All antibodies used in flow cytometry were purchased from BioLegend (San Diego, CA, USA). Interferon γ (IFNγ) and interleukin (IL)-4 enzyme-linked immunosorbent assay (ELISA) kits were purchased from Cusabio Biotechnology Co., Ltd. (Wuhan, China). Alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (CRE), blood urea nitrogen (BUN), total cholesterol (TC), triglyceride (TG), and glucose (GLU) assay kits were purchased from Nanjing Jiancheng Biological Engineering Institute (Nanjing, China).

Cell culture

Rhodopseudomonas palustris (Rp) was purchased from the China Center of Industrial Culture Collection and cultured in Van Niel’s Yeast Agar medium in a liquid anaerobic environment at 30 °C with a 40 W tungsten-filament light for illumination. The MRSA reference strain (ATCC 43300) was obtained from the Anhui Center for Surveillance of Bacterial Resistance and cultured in BHI Broth in a table concentrator (220 rpm, 37 °C).

Characterization of Rp

The morphology of Rp was characterized using a TH4-200 inverted optical microscope (Olympus, Tokyo, Japan) and a S-4800 scanning electron microscope (Hitachi, Ltd., Tokyo, Japan). The absorption spectrum of Rp was obtained using a UV–Vis spectrophotometer (Agilent Technologies, Santa Clara, CA, USA).

Preparation and mechanism of Rp@Al

Rp was mixed with different concentrations (0.25%, 0.50%, 1.00%, 1.50%, and 2.00%) of Al adjuvant to form Rp@Al gel. Thereafter, the stability of Rp@Al was monitored at different time points (Days 0, 3, and 7). To examine the preparation of Rp@Al, we measured the zeta potentials of Rp, blocked Rp, and the Al adjuvant. We mixed Rp with positively charged polyethyleneimine to block the negative charge of Rp. The blocked Rp was then mixed with Al adjuvant to determine whether the Rp@Al system could be formed.

Evaluation of the photothermal properties of Rp@Al

The photothermal properties of Rp@Al were evaluated by monitoring photothermal heating curves. Phosphate-buffered saline (PBS) and different concentrations of Rp (108, 109, and 1010 CFU/mL) were irradiated using an 808-nm laser with a power density of 2 W/cm2 for 8 min, and the photothermal heating curves were recorded. Photothermal heating curves were also recorded for Rp (109 CFU/mL) exposed to various laser power densities (0.5, 1.0, 1.5, and 2.0 W/cm2). The photothermal stability of Rp@Al was further investigated by repeated off-and-on laser irradiation (2 W/cm2 for 8 min, cooling for 10 min, four cycles).

Evaluation of antibacterial activity in vitro

Five experimental groups were defined as follows: control, Rp + NIR, Al, Rp@Al, and Rp@Al + NIR. MRSA (107 CFU/mL or 1010 CFU/mL) was cultured in the presence of PBS, Rp (109 CFU/mL), Al adjuvant (2%), and Rp@Al (gel formed by 109 CFU/mL Rp and 2% Al adjuvant), respectively. The Rp + NIR and Rp@Al + NIR groups were exposed to an 808-nm laser with a power density of 2 W/cm2 for 8 min. For colony counting analysis, the bacteria in each group were cultured for an additional 1 h at 37 °C after different treatments; thereafter, dilutions of the cultures were plated on BHI Agar and cultured at 37 °C for 24 h. Then, the colonies were counted and analyzed using the ImageJ software. For anti-biofilm analysis, after different treatments, the bacteria in each group were cultured for an additional 12 h at 37 °C to allow biofilm growth; thereafter, crystal violet staining was conducted according to the manufacturer’s instructions. In addition, to determine the reactive oxygen species (ROS) levels in the MRSA (1010 CFU/mL) after the various treatments, DCFH-DA staining was performed according to the manufacturer’s protocol. After staining, diluents of the mixture in each treatment group were coated on slides for fluorescence microscope imaging.

Animals

BALB/c mice (6–8 weeks old) were purchased from Nanjing Pharmaceutical Factory Co. Ltd. (Nanjing, China).

Evaluation of antibacterial activity and immunity response in vivo

BALB/c mice were subcutaneously (s.c.) injected with MRSA (109 CFU) to establish a cutaneous abscess model. The mice were then divided into five groups (n = 5 per group): control, Rp + NIR, Al, Rp@Al, and Rp@Al + NIR. On Day 2, mice with established abscesses were injected in situ with PBS, Rp (109 CFU), Al adjuvant (2%), or Rp@Al (the gel comprising 109 CFU Rp and 2% Al adjuvant) at the abscess site. Mice in the Rp + NIR and Rp@Al + NIR groups were exposed to an 808-nm laser with a power density of 1.5 W/cm2 for 8 min. After different treatments, abscess recovery and body weight were monitored every two days, and mice were euthanized on Day 12.

To evaluate antibacterial activity, we collected residual bacteria from the abscess sites by homogenization in a tissue homogenizer (Bertin, Montigny le Bretonneux, France). Dilutions of the supernatants were plated on BHI Agar and cultured at 37 °C for 24 h; then, the colonies were counted and analyzed with ImageJ software. To evaluate the wound healing process, skin samples collected at the abscess sites were fixed in 4% paraformaldehyde (PFA) for Masson’s trichrome staining according to the manufacturer’s instructions. Serum and the sentinel lymph nodes were collected to assess the immune response. Serum IFNγ and IL-4 levels were determined by ELISA according to the manufacturer’s instructions. Single-cell suspensions of lymph nodes were blocked with CD16/32 antibody and then divided into two parts, labeled with the following antibodies separately: FITC-CD45.2 (104), PE/Cy7-CD11c (N418), APC-CD80 (16-10A1), and PE-CD86 (A17199A); FITC-CD45.2 (104), and APC-CD4 (GK1.5). The activation of dendritic cells (DCs) and the percentage change of CD4+ T cells in lymph nodes were analyzed using a CytoFLEX flow cytometer (Beckman Coulter, Brea, CA, USA).

Evaluation of protective antimicrobial immunity induction and recurrent infection prevention

To evaluate the induction of protective antimicrobial immunity, BALB/c mice with established abscesses were treated as described above and euthanized after 4 weeks. Serum, sentinel lymph nodes, and spleens were collected to assess the immune response. Serum IFNγ and IL-4 levels were determined by ELISA according to the manufacturer’s instructions. Single-cell suspensions of lymph nodes and spleens were blocked with CD16/32 antibody and then labeled with APC/Cyanine7-CD45.2 (104) and PE-CD45R/B220 (RA3-6B2). The percentage change of B220+ B cells in lymph nodes and spleens was analyzed using the CytoFLEX flow cytometer.

To evaluate the prevention of recurrent infections, BALB/c mice with established abscesses were reared normally for 4 weeks after the initial treatment, as described above. Specifically, PBS, Rp (109 CFU), Al adjuvant (2%), or Rp@Al (a gel comprising 109 CFU Rp and 2% Al adjuvant) were injected in situ at the abscess site on day 2. Mice in the Rp + NIR and Rp@Al + NIR groups were subsequently exposed to an 808-nm laser with a power density of 1.5 W/cm2 for 8 min. After 4 weeks, mice in each group were then given a second s.c. administration of MRSA (1 × 109 CFU) or intravenous (i.v.) administration of MRSA (7.5 × 108 CFU). For the s.c. recurrent infection model, abscess recovery was monitored every 3 days, and all mice were euthanized after 12 days. Colony counting at the abscess site was performed to evaluate the antibacterial activity, and skin samples from abscess sites were fixed in 4% PFA for Masson’s trichrome staining to evaluate the wound healing process. For the i.v. recurrent infection model, the body weight of mice was monitored every day for 3 weeks, and the survival period of mice in each group was analyzed.

In vivo safety assessment

After treatment, BALB/c mice in each group were euthanized on Day 12, and the serum, heart, liver, spleen, lungs, and kidneys were collected for biochemical indicator assessment and histological evaluation. Serum biochemical indicators, including ALT, AST, CRE, BUN, TC, TG, and GLU levels, were measured using assay kits according to the corresponding manufacturer’s protocol. In addition, for histological evaluation, hematoxylin and eosin (H&E) staining of tissue sections was performed, and the tissue structure was further analyzed.

Statistical analysis

Data are shown as mean ± SD or mean ± SEM; n = 5–10. Statistical differences were analyzed using Student’s t-test (two-tailed) and indicated as ns, no significance, * P < 0.05, ** P < 0.01, *** P < 0.001, and ****P < 0.0001.

Results

Preparation and characterization of Rp@Al

The PSB used in this study was Rp, a gram-negative bacterium. Interestingly, Rp could interact with different concentrations of Al adjuvant to form Rp@Al gel in a few seconds (Fig. 1a; Fig. S1), which may be ascribed to colloid homeostasis due to charge adsorption [52]. Validating this deduction, the average zeta potentials of Rp and the Al adjuvant were found to be − 9.44 and + 11.30 mV (Fig. S2a), respectively. Positively charged polyethyleneimine was mixed with Rp to block its negative charge. Blocked Rp, with an average zeta potential of + 2.06 mV (Fig. S2a), was then mixed with Al adjuvant. Interestingly, Rp shielded from a negative charge was unable to form a composite gel system with the Al adjuvant (Fig. S2b). Different concentrations of Al adjuvant mixed with Rp formed gels with different viscosities, among which the gel formed by 2% Al adjuvant and Rp displayed good stability even for 7 days (Fig. 1b; Fig. S1). Optical microscope and scanning electron microscope images showed that Rp has a uniform cylindrical shape, with an average length of 2.6 μm (Fig. 1c, d; Fig. S3). Importantly, BChl contained in Rp showed NIR absorption at 700–1,000 nm, which is different from the visible light absorption window of plant chlorophyll. The live Rp culture appeared dark red under normal growth conditions (Fig. S4), exhibiting characteristic absorption peaks of BChl at around 805 and 865 nm, and absorption peaks of carotenoid at approximately 375 and 590 nm (Fig. 1e), which was consistent with a previous report [32]. The photothermal properties of Rp@Al were investigated under an 808-nm laser irradiation. As expected, Rp@Al exhibited excellent photothermal performance similar to that of Rp (Fig. 1f; Fig. S5). Moreover, Rp@Al showed concentration-dependent and power density-dependent photothermal effects, as indicated by photothermal images and heating curves (Fig. 1g, h; Figs. S6 and S7). In addition, Rp@Al presented commendable photothermal stability under repeated off-and-on laser irradiation (Fig. 1i), where the photothermal conversion efficiency of Rp@Al was calculated to be 36.20%, according to the method reported, which is higher than that of various photothermal agents reported to date (Fig. 1j; Table S1) [32, 53,54,55,56]. Thus, Rp@Al with prominent photothermal properties and stability was successfully prepared.

Fig. 1
figure 1

Preparation and characterization of Rp@Al with photothermal performance. a Schematic diagram of the preparation of Rp@Al composed of Rhodopseudomonas palustris (Rp) and aluminum (Al) adjuvant. b Stability of Rp@Al gel on Day 7. c, d Representative optical microscope (c) and scanning electron microscope (d) images of Rp. e Absorption spectrum of live Rp. f Photothermal temperature curves of phosphate-buffered saline (PBS), Rp, and Rp@Al under an 808-nm laser with a power density of 2 W/cm2 for 8 min. g Photothermal temperature curves of PBS and different concentrations of Rp@Al under an 808-nm laser with a power density of 2 W/cm2 for 8 min. h Photothermal temperature curves of Rp@Al under an 808-nm laser with different power densities for 8 min. i Photothermal stability of Rp@Al under an 808-nm laser with a power density of 2 W/cm2 for four irradiation/cooling cycles. j Photothermal conversion efficiency of Rp@Al

Full size image

Photothermal antibacterial activity of Rp@Al in vitro

Encouraged by the photothermal performance of Rp@Al, we next examined the antibacterial and anti-biofilm efficiencies of Rp@Al using gram-positive MRSA. After irradiation at 2 W/cm2 for 8 min, the relative bacterial viability in the Rp + NIR and Rp@Al + NIR groups was only 2.11% and 1.56%, respectively. The antibacterial efficiency of Al and Rp@Al alone was also examined, and the results showed that Al and Rp@Al alone had no obvious antibacterial effect (Fig. 2a, b), indicating that the antibacterial activity of Rp@Al should be attributed to its photothermal properties. Bacterial biofilm is one of the causes of antibiotic tolerance. In this regard, the MRSA biofilm disruption after different treatments was verified using crystal violet staining. Compared with those in the control group, biofilms were severely damaged in the Rp + NIR and Rp@Al + NIR groups, while there was no significant difference in Al and Rp@Al groups (Fig. 2c, d). These findings suggested that Rp@Al exhibited a potent anti-biofilm efficiency against MRSA through its photothermal effect. Local hyperthermia may destroy bacterial structures by producing ROS or denaturing protein structure, ultimately resulting in bacterial death [57]. Hence, DCFH-DA staining was performed to reveal the ROS levels in the MRSA after the various treatments (Fig. S8). The results suggest that the photothermal antibacterial mechanism of Rp@Al may be attributed to the production of ROS that destroy bacterial structures, eventually killing the bacteria. In conclusion, the Rp@Al developed in this study integrates the advantages of organic and inorganic nanomaterials for antibacterial applications, as summarized in Table S2 [58, 59], exhibiting prominent photothermal antibacterial and anti-biofilm abilities (Fig. 2e).

Fig. 2
figure 2

Antibacterial activity of Rp@Al in vitro. a, b Culture plate images (a) and quantitative analysis (b) showing the antibacterial ability of different treatments (mean ± SD, n = 5). c, d Crystal violet staining images (c) and quantitative analysis (d) showing the anti-biofilm ability of different treatments (mean ± SD, n = 5). e Schematic diagram showing the antibacterial and anti-biofilm performance of Rp@Al. ns, no significance, ****P < 0.0001

Full size image

Rp@Al exerts excellent antibacterial activity and enhances the TH-type immune response in vivo

We next explored the antibacterial activity of Rp@Al and the immune response elicited by Rp@Al in mice with cutaneous abscesses generated by s.c. administration of MRSA. On Day 2, the different treatments were administered; the local temperature of the abscess site rose to approximately 49 °C in the Rp + NIR and Rp@Al + NIR groups (Fig. S9). The abscesses were photographed and body weights were measured every 2 days. All mice were euthanized at the end of treatment (Day 12), and the antibacterial activity and immune response were evaluated (Fig. 3a). Images of abscesses showed that the recovery in the Rp + NIR and Rp@Al + NIR groups was better than that in the control group, while the abscesses in the Al and Rp@Al groups showed no significant recovery (Fig. 3b), corroborating the commendable photothermal antibacterial ability of Rp@Al. To validate this, we performed bacterial colony counting at the abscess site. As expected, the results showed that compared with that in the control group, the relative bacterial viability in the Rp + NIR and Rp@Al + NIR groups was significantly decreased and was only 0.85% and 0.13%, respectively, whereas that in the Al and Rp@Al groups showed no significant difference (Fig. 3c, d). In addition, Masson’s trichrome staining of the skin at the abscess site showed more collagen deposition in the Rp + NIR and Rp@Al + NIR groups than that in the control group, while the collagen deposition in the Al and Rp@Al groups showed no significant change (Fig. 3e; Fig. S10). This confirmed that Rp@Al effectively promotes abscess recovery via its distinguished photothermal antibacterial ability.

Fig. 3
figure 3

Evaluation of Rp@Al-based antibacterial activity and immune response in vivo. a Schematic illustration of abscess model establishment and therapeutic strategy. b Time-lapse images of methicillin-resistant Staphylococcus aureus (MRSA)-induced abscess recovery after different treatments. c, d Culture plate images (c) and quantitative analysis (d) showing the in vivo antibacterial ability of different treatments (mean ± SEM, n = 5). e Masson’s trichrome staining of skin tissues at abscess sites after different treatments. f Percentage of CD86+ CD80+ dendritic cells (DCs) in CD11c+ DCs in lymph nodes from mice in different treatment groups (mean ± SEM, n = 5). g Percentage of CD4+ T cells in total leukocytes isolated from lymph nodes harvested from different treatment groups (mean ± SEM, n = 5). h, i Quantitative analysis of serum interleukin (IL)-4 (h) and interferon γ (IFNγ) (i) levels on Day 12 (mean ± SEM, n = 5). ns, no significance, *P < 0.05, **P < 0.01, and ****P < 0.0001

Full size image

To assess the immune response elicited by Rp@Al, we collected sentinel lymph nodes and serum from the euthanized mice for analysis. We first evaluated the activation of DCs, the main antigen-presenting cells. Notably, compared with that in the control group, the percentage of CD86+ CD80+ DCs in CD11c+ DCs was significantly increased in both the Al, Rp@Al, and Rp@Al + NIR groups, while that in the Rp + NIR group showed no significant increase (Fig. 3f). The proportion of CD4+ T cells in the Al, Rp@Al, and Rp@Al + NIR groups was also upregulated compared with that in the control group (Fig. 3g; Fig. S11). Together, these findings indicated that Rp@Al may have enhanced the antigen presentation of activated DCs to prime naive CD4+ T cells. Polarization of CD4+ T cells into T helper 1 (TH1) and TH2 is crucial for induction of protective antimicrobial immunity [60]. In view of this, the levels of IL-4 and IFNγ in serum were determined using ELISA. IL-4 and IFNγ production are critical features of TH2 and TH1 cell responses, respectively [60]. The levels of IL-4 and IFNγ in the Al, Rp@Al, and Rp@Al + NIR groups increased significantly, while neither the IL-4 nor IFNγ level in the Rp + NIR group showed significant differences when compared with those in the control group (Fig. 3h, i). This initiation of TH-type immune response induced by Rp@Al may be attributed to the Al adjuvant, as they are reported to prime TH cell responses preferentially [50]. In conclusion, Rp@Al elicited not only prominent antibacterial activities but also enhanced TH1/TH2 immune response.

Adjuvant-like Rp@Al effectively prevents recurrent infection by inducing pathogen-specific immunological memory

Given that Rp@Al induced TH-type immune responses, we next evaluated the generation of immune memory in abscess-bearing mice after Rp@Al treatment. BALB/c mice with MRSA-infected abscesses were grouped and treated as described above (Fig. 4a). We first verified the TH1/TH2 immune responses primed by Rp@Al by measuring serum levels of IL-4 and IFNγ using ELISA. Compared with those in the control group, the levels of IL-4 and IFNγ in the Al, Rp@Al, and Rp@Al + NIR groups were significantly increased, while they were not significantly different in the Rp + NIR group (Fig. 4b, c). Furthermore, memory B cells in sentinel lymph nodes and spleens were analyzed by flow cytometry. Compared with those in the control group, the percentages of B220+ B cells in lymph nodes and spleens in the Al, Rp@Al, and Rp@Al + NIR groups were significantly increased, while those in the Rp + NIR group showed no significant difference (Fig. 4d, e; Fig. S12), suggesting that immune memory was evoked after Rp@Al treatment.

Fig. 4
figure 4

Rp@Al-based protective immunity prevents MRSA-induced recurrent infections by eliciting pathogen-specific immunological memory. a Schematic illustration of the evaluation of protective immunity and prevention of MRSA-induced recurrent infections. Mice were injected subcutaneously (s.c.) with MRSA (109 CFU, first exposure) followed by different treatments on Day 2. After 4 weeks, serum, lymph nodes, and spleens of mice in different treatment groups were collected for protective immunity analysis. Prevention of recurrent infections was evaluated by s.c. re-infection with MRSA(109 CFU, second exposure). b, c Quantitative analysis of serum IL-4 (b) and IFNγ (c) levels on Day 30 (mean ± SEM, n = 5). d, e Percentage of CD45+ B220+ memory B cells in lymph nodes (d) and spleens (e) from mice in different treatment groups on Day 30 (mean ± SEM, n = 5). f, g Culture plate images (f) and quantitative analysis (g) showing the antibacterial ability of different treatments after s.c. re-infection with MRSA (mean ± SEM, n = 5). h Schematic diagram showing the mechanism of Rp@Al-based prevention of recurrent infections with MRSA. ns, no significance, *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001

Full size image

To evaluate the preventive effect of immune memory against recurrent infections after initial Rp@Al treatment, we reared mice normally for 4 weeks and then administered a second dose of MRSA s.c. and monitored abscess recovery as described (Fig. 4a). Interestingly, bacterial counts were lower and abscess recovery was faster in the Al, Rp@Al, and Rp@Al + NIR groups than in the Rp + NIR and control groups (Fig. 4f, g; Fig. S13). Additionally, Masson’s trichrome staining of the skin at the abscess site showed more collagen deposition in the Al, Rp@Al, and Rp@Al + NIR groups than in the Rp + NIR and control groups (Fig. S14), further demonstrating the enhanced abscess healing after Rp@Al treatment. Together, these findings suggested that a protective antimicrobial immunity evoked by Rp@Al could effectively prevent recurrent infections with drug-resistant bacteria (Fig. 4h).

To further confirm the protective effect of pathogen-specific immunological memory elicited by Rp@Al, mice were housed for 4 weeks after the initial treatment and were then i.v. re-infected with MRSA at a near-lethal infection dose. Body weight and the survival of mice in each group were monitored (Fig. 5a). No significant difference was observed in the initial body weight of mice among the different groups (Fig. S15). Encouragingly, compared with that in the control and Rp + NIR groups, the survival rate of mice in the Al, Rp@Al, and Rp@Al + NIR groups was significantly increased by up to 60–70%, and the survival period of mice in these groups was also significantly increased (Fig. 5b). Specifically, mice in both the control and Rp + NIR groups rapidly lost weight and did not survive past 5 and 9 days, respectively (Fig. 5c, d), whereas the weight of mice in the Al, Rp@Al, and Rp@Al + NIR groups returned to the normal range after approximately 1 week (Fig. 5e–g), although the body weight of mice in each group showed a downward trend upon second infection. In conclusion, adjuvant-like Rp@Al effectively prevented recurrent infections with drug-resistant bacteria by inducing pathogen-specific immunological memory.

Fig. 5
figure 5

Rp@Al-based prevention of MRSA-induced recurrent infections and improvement of the survival rate. a Schematic representation illustrating the prevention of MRSA-induced recurrent infections. Mice were injected s.c. with MRSA (109 CFU, first exposure) followed by different treatments on Day 2. After 4 weeks, prevention of recurrent infections was evaluated by i.v. re-infection with MRSA (7.5 × 108 CFU, second exposure). b Survival curve of mice in different treatment groups after i.v. re-infection with MRSA (n = 10). c–g Body weight monitoring of mice in different treatment groups after i.v. re-infection with MRSA (n = 10)

Full size image

Biosafety assessment of Rp@Al

We next evaluated the biosafety of the multiplex system. The weight of mice in each treatment group did not show a downward trend, indicating the biosafety of the treatment system to some extent (Fig. 6a). Mice were euthanized at the end of treatment for the analysis of biochemical indicators and organ safety. There were no significant differences in serum ALT and AST levels among the Rp + NIR, Al, Rp@Al, and Rp@Al + NIR groups compared with those in the control group (Fig. 6b, c), indicating that the treatment system did not affect the liver function of mice. Moreover, there were no significant differences in CRE and BUN levels among the Rp + NIR, Al, Rp@Al, and Rp@Al + NIR groups when compared with those in the control group (Fig. 6d, e), suggesting that the treatment system had no significant influence on the renal function of mice. TC, TG, and GLU levels in mice in each treatment group also showed no significant differences, further confirming the biosafety of the treatment system (Fig. 6f–h). Furthermore, the evaluation of organ safety of the treatment system revealed no systematic toxicity to the heart, liver, spleen, lungs, and kidneys of mice in each treatment group, as assessed by H&E staining (Fig. 6i). Taken together, these findings suggested the biosafety of the multiplex system prepared herein.

Fig. 6
figure 6

In vivo biosafety evaluation of Rp@Al. a Body weight monitoring of mice in different treatment groups. b–h Analysis of serum biochemical indicators of mice from different groups at the end of treatment (mean ± SEM, n = 5). i Representative hematoxylin and eosin (H&E) staining images showing the major organ tissue structures of mice in different treatment groups. ns, no significance

Full size image

Discussion

The high mortality associated with drug-resistant bacteria and its recurrent infections is an intractable clinical problem [61]. It is challenging to achieve the treatment of drug-resistant bacteria and the prevention of their recurrent infection simultaneously using existing strategies [37, 44, 45, 62]. In this study, a PSB-based multiplex system, Rp@Al, was successfully developed for the treatment and prevention of drug-resistant bacterial infections. Rp@Al, containing BChl that absorbs NIR light at around 805 and 865 nm, exhibited prominent stability and photothermal capability, with a photothermal conversion efficiency of 36.20% and up to 98.44% antibacterial efficacy in vitro. Furthermore, in a MRSA-infected cutaneous abscess model, we demonstrated that Rp@Al also displayed a predominant photothermal antibacterial effect, effectively enhancing abscess recovery. Taken together, these results suggested that the PSB-based Rp@Al can be used as a novel photothermal reagent, which has great potential for photothermal treatment of drug-resistant bacterial infections.

Immunomodulatory therapy, which exploit host-dependent natural mechanisms to activate or strengthen protective antimicrobial immunity, is a potential approach for preventing recurrent infection with drug-resistant bacteria [37,38,39,40,41,42,43]. Encouragingly, Rp@Al could strengthen the activation of DCs and TH1/TH2 immune responses, resulting in a strong pathogen-specific immunological memory against recurrent infections after initial treatment. This may be ascribed to the Al adjuvant, which has been reported to preferentially prime CD4+ T cells and further activate B cells, thereby initiating an adaptive immune response [50, 51]. The protective antimicrobial immunity was further confirmed in a MRSA-induced recurrent infection model. Upon second infection, Rp@Al-treated mice showed lower bacterial activity, faster abscess recovery, and a higher survival rate of up to 70% even under near-lethal doses than control mice. Furthermore, synthetic evaluation suggested that Rp@Al had adequate biosafety. Taken together, these results suggested that the adjuvant-like Rp@Al can effectively prevented recurrent infections via protective immunomodulatory effect.

These unique features of the multiplex system developed herein indicate its potential application toward the design of efficient treatment and prevention regimes for drug-resistant bacterial infections. Furthermore, it is also challenging to integrate these properties into a single system, demonstrating this could potentially stimulate further research in developing multiplex system for other applications.

Conclusions

In summary, we presented a multiplex system that utilizes photothermal ablation to achieve drug-resistant bacteria abrogation, while also preventing recurrent infections with drug-resistant bacteria through adjuvant-like modulation of the host immune response. Specifically, we i) developed a PSB-based multiplex system (Rp@Al) that was fabricated through electrostatic-driven self-assembly for combating drug-resistant bacterial infections; ii) demonstrated that Rp@Al, containing BChl, which absorbs NIR light at around 805 and 865 nm, exhibited prominent photothermal properties and photothermal ablation ability toward drug-resistant bacteria; iii) revealed that Rp@Al exerts an adjuvant-like effect to enhance the antigen presentation of activated DCs, thereby priming TH1/TH2 immune responses, resulting in a protective pathogen-specific immunological memory against recurrent infections with drug-resistant bacteria; and iv) illustrated that Rp@Al not only eliminates drug-resistant bacteria through photothermal killing but also plays a preventive role in reducing infection burden and prolonging the survival period of mice during recurrent infections (Fig. 7).

Fig. 7
figure 7

Schematic illustration of PSB-based multiplex system for the treatment of drug-resistant bacterial infections. Photosynthetic bacteria (PSB)-based Rp@Al, fabricated through an electrostatic-driven self-assembly process, containing bacteriochlorophyll (BChl) that absorbs near-infrared (NIR) light at around 805 and 865 nm, exhibited effective photothermal ablation of MRSA. Rp@Al also exerted an adjuvant-like effect to enhance the antigen presentation of activated DCs, thereby priming the T helper 1 (TH1)/TH2 immune response, resulting in a protective pathogen-specific immunological memory against recurrent infections with the same drug-resistant bacteria

Full size image

Availability of data and materials

The data that support the findings of this study are available from the corresponding authors upon reasonable request.

Abbreviations

AMR:

Antimicrobial resistance

MRSA :

Methicillin-resistant Staphylococcus aureus

PSB:

Photosynthetic bacteria

BChl:

Bacteriochlorophyll

NIR:

Near-infrared

PRRs:

Pattern recognition receptors

TLRs:

Toll-like receptors

NLRs:

NOD-like receptors

BHI:

Brain Heart Infusion

IFNγ:

Interferon γ

IL:

Interleukin

ELISA:

Enzyme-linked immunosorbent assay

ALT:

Alanine aminotransferase

AST:

Aspartate aminotransferase

CRE:

Creatinine

BUN:

Blood urea nitrogen

TC:

Total cholesterol

TG:

Triglyceride

GLU:

Glucose

Rp:

Rhodopseudomonas palustris

PBS:

Phosphate-buffered saline

PFA:

Paraformaldehyde

DCs:

Dendritic cells

H&E:

Hematoxylin and eosin

References

  1. Baym M, Stone LK, Kishony R. Multidrug evolutionary strategies to reverse antibiotic resistance. Science. 2016;351:aad3292. https://doi.org/10.1126/science.aad3292.

    Article  CAS  Google Scholar 

  2. Theuretzbacher U, Outterson K, Engel A, Karlén A. The global preclinical antibacterial pipeline. Nat Rev Microbiol. 2020;18:275–85. https://doi.org/10.1038/s41579-019-0288-0.

    Article  CAS  Google Scholar 

  3. Lewis K. The science of antibiotic discovery. Cell. 2020;181:29–45. https://doi.org/10.1016/j.cell.2020.02.056.

    Article  CAS  Google Scholar 

  4. Davies J, Davies D. Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev. 2010;74:417–33. https://doi.org/10.1128/MMBR.00016-10.

    Article  CAS  Google Scholar 

  5. Murray CJ, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399:629–55. https://doi.org/10.1016/S0140-6736(21)02724-0.

    Article  CAS  Google Scholar 

  6. O’Neill J. Tackling drug-resistant infections globally: final report and recommendations, Rev Antimicrob Resist. 2016. https://amr-review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf.

  7. Schrader SM, Vaubourgeix J, Nathan C. Biology of antimicrobial resistance and approaches to combat it. Sci Transl Med. 2020;12:eaaz6992. https://doi.org/10.1126/scitranslmed.aaz6992.

    Article  CAS  Google Scholar 

  8. Wu Y, Jiang W, Huo S, Li S, Xu Y, Ding S, et al. Nano-metal–organic-frameworks for treating H2O2-secreting bacteria alleviate pulmonary injury and prevent systemic sepsis. Biomaterials. 2021;279:121237. https://doi.org/10.1016/j.biomaterials.2021.121237.

    Article  CAS  Google Scholar 

  9. Turner NA, Sharma-Kuinkel BK, Maskarinec SA, Eichenberger EM, Shah PP, Carugati M, et al. Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research. Nat Rev Microbiol. 2019;17:203–18. https://doi.org/10.1038/s41579-018-0147-4.

    Article  CAS  Google Scholar 

  10. Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W, et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science. 2000;289:1352–5. https://doi.org/10.1126/science.289.5483.1352.

    Article  CAS  Google Scholar 

  11. Tan L, Fu J, Feng F, Liu X, Cui Z, Li B, et al. Engineered probiotics biofilm enhances osseointegration via immunoregulation and anti-infection. Sci Adv. 2020;6:eaba5723. https://doi.org/10.1126/sciadv.aba5723.

    Article  CAS  Google Scholar 

  12. Yi X, Zhou H, Chao Y, Xiong S, Zhong J, Chai Z, et al. Bacteria-triggered tumor-specific thrombosis to enable potent photothermal immunotherapy of cancer. Sci Adv. 2020;6:eaba3546. https://doi.org/10.1126/sciadv.aba3546.

    Article  CAS  Google Scholar 

  13. Chen Q-W, Liu X, Fan J-X, Peng S, Wang J, Wang X, et al. Self-mineralized photothermal bacteria hybridizing with mitochondria-targeted metal–organic frameworks for augmenting photothermal tumor therapy. Adv Funct Mater. 2020;30:1909806. https://doi.org/10.1002/adfm.201909806.

    Article  CAS  Google Scholar 

  14. Zhong D, Li W, Qi Y, He J, Zhou M. Photosynthetic biohybrid nanoswimmers system to alleviate tumor hypoxia for FL/PA/MR imaging-guided enhanced radio-photodynamic synergetic therapy. Adv Funct Mater. 2020;30:1910395. https://doi.org/10.1002/adfm.201910395.

    Article  CAS  Google Scholar 

  15. Li W, Wang S, Zhong D, Du Z, Zhou M. A bioactive living hydrogel: photosynthetic bacteria mediated hypoxia elimination and bacteria-killing to promote infected Wound healing. Adv Therap. 2021;4:2000107. https://doi.org/10.1002/adtp.202000107.

    Article  CAS  Google Scholar 

  16. Wang S-B, Liu X-H, Li B, Fan J, Ye J, Cheng H, et al. Bacteria-assisted selective photothermal therapy for precise tumor inhibition. Adv Funct Mater. 2019;29:1904093. https://doi.org/10.1002/adfm.201904093.

    Article  CAS  Google Scholar 

  17. Qiao Y, Yang F, Xie T, Du Z, Zhong D, Qi Y, et al. Engineered algae: a novel oxygen-generating system for effective treatment of hypoxic cancer. Sci Adv. 2020;6:eaba5996. https://doi.org/10.1126/sciadv.aba5996.

    Article  CAS  Google Scholar 

  18. Zhong D, Zhang D, Xie T, Zhou M. Biodegradable microalgae-based carriers for targeted delivery and imaging-guided therapy toward lung metastasis of breast cancer. Small. 2020;16:e2000819. https://doi.org/10.1002/smll.202000819.

    Article  CAS  Google Scholar 

  19. Riglar DT, Silver PA. Engineering bacteria for diagnostic and therapeutic applications. Nat Rev Microbiol. 2018;16:214–25. https://doi.org/10.1038/nrmicro.2017.172.

    Article  CAS  Google Scholar 

  20. Huang X, Pan J, Xu F, Shao B, Wang Y, Guo X, et al. Bacteria-based cancer immunotherapy. Adv Sci (Weinh). 2021;8:2003572. https://doi.org/10.1002/advs.202003572.

    Article  CAS  Google Scholar 

  21. Zheng JH, Nguyen VH, Jiang SN, Park SH, Tan W, Hong SH, et al. Two-step enhanced cancer immunotherapy with engineered Salmonella typhimurium secreting heterologous flagellin. Sci Transl Med. 2017;9:eaak9537. https://doi.org/10.1126/scitranslmed.aak9537.

    Article  CAS  Google Scholar 

  22. Gao C, Wang Q, Li J, Kwong CHT, Wei J, Xie B, et al. In vivo hitchhiking of immune cells by intracellular self-assembly of bacteria-mimetic nanomedicine for targeted therapy of melanoma. Sci Adv. 2022;8:eabn1805. https://doi.org/10.1126/sciadv.abn1805.

    Article  CAS  Google Scholar 

  23. Chowdhury S, Castro S, Coker C, Hinchliffe TE, Arpaia N, Danino T. Programmable bacteria induce durable tumor regression and systemic antitumor immunity. Nat Med. 2019;25:1057–63. https://doi.org/10.1038/s41591-019-0498-z.

    Article  CAS  Google Scholar 

  24. Zheng DW, Chen Y, Li ZH, Xu L, Li CX, Li B, et al. Optically controlled bacterial metabolite for cancer therapy. Nat Commun. 2018;9:1680. https://doi.org/10.1038/s41467-018-03233-9.

    Article  CAS  Google Scholar 

  25. Gareau MG, Sherman PM, Walker WA. Probiotics and the gut microbiota in intestinal health and disease. Nat Rev Gastroenterol Hepatol. 2010;7:503–14. https://doi.org/10.1038/nrgastro.2010.117.

    Article  Google Scholar 

  26. Liévin-Le Moal VL-L, Servin AL. Anti-infective activities of lactobacillus strains in the human intestinal microbiota: from probiotics to gastrointestinal anti-infectious biotherapeutic agents. Clin Microbiol Rev. 2014;27:167–99. https://doi.org/10.1128/CMR.00080-13.

    Article  CAS  Google Scholar 

  27. Liu X, Huang L, Rensing C, Ye J, Nealson KH, Zhou S. Syntrophic interspecies electron transfer drives carbon fixation and growth by Rhodopseudomonas palustris under dark, anoxic conditions. Sci Adv. 2021;7:eabn1852. https://doi.org/10.1126/sciadv.abh1852.

    Article  CAS  Google Scholar 

  28. Lu H, Zhang G, Wan T, Lu Y. Influences of light and oxygen conditions on photosynthetic bacteria macromolecule degradation: different metabolic pathways. Bioresour Technol. 2011;102:9503–8. https://doi.org/10.1016/j.biortech.2011.07.114.

    Article  CAS  Google Scholar 

  29. Lu H, Zhang G, Zheng Z, Meng F, Du T, He S. Bio-conversion of photosynthetic bacteria from non-toxic wastewater to realize wastewater treatment and bioresource recovery: a review. Bioresour Technol. 2019;278:383–99. https://doi.org/10.1016/j.biortech.2019.01.070.

    Article  CAS  Google Scholar 

  30. Shu X, Royant A, Lin MZ, Aguilera TA, Lev-Ram V, Steinbach PA, et al. Mammalian expression of infrared fluorescent proteins engineered from a bacterial phytochrome. Science. 2009;324:804–7. https://doi.org/10.1126/science.1168683.

    Article  Google Scholar 

  31. Ryu MH, Kang IH, Nelson MD, Jensen TM, Lyuksyutova AI, Siltberg-Liberles J, et al. Engineering adenylate cyclases regulated by near-infrared window light. Proc Natl Acad Sci U S A. 2014;111:10167–72. https://doi.org/10.1073/pnas.1324301111.

    Article  CAS  Google Scholar 

  32. Zheng P, Fan M, Liu H, Zhang Y, Dai X, Li H, et al. Self-propelled and near-infrared-phototaxic photosynthetic bacteria as photothermal agents for hypoxia-targeted cancer therapy. ACS Nano. 2021;15:1100–10. https://doi.org/10.1021/acsnano.0c08068.

    Article  CAS  Google Scholar 

  33. Makabenta JMV, Nabawy A, Li CH, Schmidt-Malan S, Patel R, Rotello VM. Nanomaterial-based therapeutics for antibiotic-resistant bacterial infections. Nat Rev Microbiol. 2021;19:23–36. https://doi.org/10.1038/s41579-020-0420-1.

    Article  CAS  Google Scholar 

  34. Guo B, Huang Z, Shi Q, Middha E, Xu S, Li L, et al. Organic small molecule based photothermal agents with molecular rotors for malignant breast cancer therapy. Adv Funct Mater. 2020;30:1907093. https://doi.org/10.1002/adfm.201907093.

    Article  CAS  Google Scholar 

  35. Zhang L, Liu Y, Huang H, Xie H, Zhang B, Xia W, et al. Multifunctional nanotheranostics for near infrared optical imaging-guided treatment of brain tumors. Adv Drug Deliv Rev. 2022;190:114536. https://doi.org/10.1016/j.addr.2022.114536.

    Article  CAS  Google Scholar 

  36. Zhang L, Forgham H, Huang X, Shen A, Davis TP, Qiao R, et al. All-in-one inorganic nanoagents for near-infrared-II photothermal-based cancer theranostics. Materials Today Advances. 2022;14:100226. https://doi.org/10.1016/j.mtadv.2022.100226.

    Article  CAS  Google Scholar 

  37. Hancock REW, Nijnik A, Philpott DJ. Modulating immunity as a therapy for bacterial infections. Nat Rev Microbiol. 2012;10:243–54. https://doi.org/10.1038/nrmicro2745.

    Article  CAS  Google Scholar 

  38. Pernet E, Guillemot L, Burgel PR, Martin C, Lambeau G, Sermet-Gaudelus I, et al. Pseudomonas aeruginosa eradicates Staphylococcus aureus by manipulating the host immunity. Nat Commun. 2014;5:5105. https://doi.org/10.1038/ncomms6105.

    Article  CAS  Google Scholar 

  39. Kim B, Pang HB, Kang J, Park JH, Ruoslahti E, Sailor MJ. Immunogene therapy with fusogenic nanoparticles modulates macrophage response to Staphylococcus aureus. Nat Commun. 2018;9:1969. https://doi.org/10.1038/s41467-018-04390-7.

    Article  CAS  Google Scholar 

  40. Tang H, Qu X, Zhang W, Chen X, Zhang S, Xu Y, et al. Photosensitizer nanodot eliciting immunogenicity for photo-immunologic therapy of postoperative methicillin-resistant Staphylococcus aureus infection and secondary recurrence. Adv Mater. 2022;34:e2107300. https://doi.org/10.1002/adma.202107300.

    Article  CAS  Google Scholar 

  41. Fu J, Li Y, Zhang Y, Liang Y, Zheng Y, Li Z, et al. An engineered pseudo-macrophage for rapid treatment of bacteria-infected osteomyelitis via microwave-excited anti-infection and immunoregulation. Adv Mater. 2021;33:e2102926. https://doi.org/10.1002/adma.202102926.

    Article  CAS  Google Scholar 

  42. Wei X, Ran D, Campeau A, Xiao C, Zhou J, Dehaini D, et al. Multiantigenic nanotoxoids for antivirulence vaccination against antibiotic-resistant gram-negative bacteria. Nano Lett. 2019;19:4760–9. https://doi.org/10.1021/acs.nanolett.9b01844.

    Article  CAS  Google Scholar 

  43. Wang C, Xiao Y, Zhu W, Chu J, Xu J, Zhao H, et al. Photosensitizer-modified MnO2 nanoparticles to enhance photodynamic treatment of abscesses and boost immune protection for treated mice. Small. 2020;16:e2000589. https://doi.org/10.1002/smll.202000589.

    Article  CAS  Google Scholar 

  44. Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med. 2002;347:1151–60. https://doi.org/10.1056/NEJMoa021481.

    Article  CAS  Google Scholar 

  45. Hennessy EJ, Parker AE, O’Neill LAJ. Targeting toll-like receptors: emerging therapeutics? Nat Rev Drug Discov. 2010;9:293–307. https://doi.org/10.1038/nrd3203.

    Article  CAS  Google Scholar 

  46. Sorbara MT, Philpott DJ. Peptidoglycan: a critical activator of the mammalian immune system during infection and homeostasis. Immunol Rev. 2011;243:40–60. https://doi.org/10.1111/j.1600-065X.2011.01047.x.

    Article  CAS  Google Scholar 

  47. Dunne A, O’Neill LAJ. The interleukin-1 receptor/toll-like receptor superfamily: signal transduction during inflammation and host defense. Sci STKE. 2003;2003:re3. https://doi.org/10.1126/stke.2003.171.re3.

    Article  Google Scholar 

  48. Zaheer SA, Mukherjee R, Ramkumar B, Misra RS, Sharma AK, Kar HK, et al. Combined multidrug and Mycobacterium w vaccine therapy in patients with multibacillary leprosy. J Infect Dis. 1993;167:401–10. https://doi.org/10.1093/infdis/167.2.401.

    Article  CAS  Google Scholar 

  49. Klinman DM, Xie H, Ivins BE. CpG oligonucleotides improve the protective immune response induced by the licensed anthrax vaccine. Ann N Y Acad Sci. 2006;1082:137–50. https://doi.org/10.1196/annals.1348.030.

    Article  CAS  Google Scholar 

  50. Marrack P, McKee AS, Munks MW. Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol. 2009;9:287–93. https://doi.org/10.1038/nri2510.

    Article  CAS  Google Scholar 

  51. Eisenbarth SC, Colegio OR, O’Connor W, Sutterwala FS, Flavell RA. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature. 2008;453:1122–6. https://doi.org/10.1038/nature06939.

    Article  CAS  Google Scholar 

  52. Jiang H, Wang Q, Li L, Zeng Q, Li H, Gong T, et al. Turning the old adjuvant from gel to nanoparticles to amplify CD8+ T cell responses. Adv Sci (Weinh). 2018;5:1700426. https://doi.org/10.1002/advs.201700426.

    Article  CAS  Google Scholar 

  53. Hessel CM, Pattani VP, Rasch M, Panthani MG, Koo B, Tunnell JW, et al. Copper selenide nanocrystals for photothermal therapy. Nano Lett. 2011;11:2560–6. https://doi.org/10.1021/nl201400z.

    Article  CAS  Google Scholar 

  54. Li Y, Bai G, Zeng S, Hao J. Theranostic carbon dots with innovative NIR-II emission for in vivo renal-excreted optical imaging and photothermal therapy. ACS Appl Mater Interfaces. 2019;11:4737–44. https://doi.org/10.1021/acsami.8b14877.

    Article  CAS  Google Scholar 

  55. Sun Z, Xie H, Tang S, Yu XF, Guo Z, Shao J, et al. Ultrasmall black phosphorus quantum dots: synthesis and use as photothermal agents. Angew Chem Int Ed Engl. 2015;54:11526–30. https://doi.org/10.1002/anie.201506154.

    Article  CAS  Google Scholar 

  56. Ding Y, Wang C, Lu B, Yao Y. Enhancing the stability and photothermal conversion efficiency of ICG by pillar[5]arene-Based Host-Guest Interaction. Front Chem. 2021;9:775436. https://doi.org/10.3389/fchem.2021.775436.

    Article  CAS  Google Scholar 

  57. Bellier N, Baipaywad P, Ryu N, Lee JY, Park H. Recent biomedical advancements in graphene oxide- and reduced graphene oxide-based nanocomposite nanocarriers. Biomater Res. 2022;26:65. https://doi.org/10.1186/s40824-022-00313-2.

    Article  CAS  Google Scholar 

  58. Huang H, Ali A, Liu Y, Xie H, Ullah S, Roy S, et al. Advances in image-guided drug delivery for antibacterial therapy. Adv Drug Deliv Rev. 2023;192:114634. https://doi.org/10.1016/j.addr.2022.114634.

    Article  CAS  Google Scholar 

  59. Quintero-Quiroz C, Acevedo N, Zapata-Giraldo J, Botero LE, Quintero J, Zárate-Triviño D, et al. Optimization of silver nanoparticle synthesis by chemical reduction and evaluation of its antimicrobial and toxic activity. Biomater Res. 2019;23:1–15. https://doi.org/10.1186/s40824-019-0173-y.

    Article  Google Scholar 

  60. Abebe F. Synergy between Th1 and Th2 responses during Mycobacterium tuberculosis infection: a review of current understanding. Int Rev Immunol. 2019;38:172–9. https://doi.org/10.1080/08830185.2019.1632842.

    Article  CAS  Google Scholar 

  61. Mullard A. The deadly burden of drug-resistant bacteria. Nat Rev Drug Discov. 2022;21:170. https://doi.org/10.1038/d41573-022-00034-0.

    Article  CAS  Google Scholar 

  62. Zhu Y, Hao W, Wang X, Ouyang J, Deng X, Yu H, et al. Antimicrobial peptides, conventional antibiotics, and their synergistic utility for the treatment of drug-resistant infections. Med Res Rev. 2022;42:1377–422. https://doi.org/10.1002/med.21879.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We acknowledge the Anhui Center for Surveillance of Bacterial Resistance for providing the MRSA strain and the China Center of Industrial Culture Collection for providing the Rp strain.

Funding

This work was supported by the National Natural Science Foundation of China [grant numbers 81871788 and 32171375]; the Outstanding Youth Fund of Natural Science Foundation of Anhui Province [grant number 2108085J41]; the Key Research and Development Program of Anhui Province [grant number 202004j07020013]; the Anhui Provincial Postdoctoral Science Foundation [grant number 2019 B302]; the Scientific Research Fund of Anhui Education Office [grant number 2020jyxm2316]; and the Anhui Province Natural Science Foundation (grant numbers 1908085MH263).

Author information

Author notes

  1. Youcui Xu, Yi Wu and Yi Hu contributed equally to this work.

Authors and Affiliations

  1. Medical Research Center, Guangdong Cardiovascular Institute, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, 510080, Guangdong, China

    Youcui Xu, Xiaowan Huang & Longping Wen

  2. Department of Radiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230001, Anhui, China

    Yi Wu

  3. Center for Biomedical Imaging, University of Science and Technology of China, Hefei, 230026, Anhui, China

    Yi Hu

  4. Department of Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230001, Anhui, China

    Mengran Xu

  5. Department of Infectious Diseases, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, Anhui, China

    Yanyan Liu, Yuting Ding & Jiabin Li

  6. School of Life Sciences, Hefei Normal University, Hefei, 230601, Anhui, China

    Jing Chen

  7. Department of Orthopaedics, Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, 230001, Anhui, China

    Chen Zhu

Authors
  1. Youcui Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yi Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yi Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mengran Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yanyan Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yuting Ding
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jing Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Xiaowan Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Longping Wen
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jiabin Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Chen Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Y.C.X., Y.W., and Y.H. contributed equally to this work. Y.C.X., and Y.W. designed the experiments. Y.C.X., Y.W., Y.H., M.R.X., Y.T.D., X.W.H., and J.C. performed the experiments. Y.C.X., Y.W., and Y.Y.L. analyzed the data. L.P.W., J.B.L., and C.Z. wrote the paper. The authors read and approved the final manuscript.

Corresponding authors

Correspondence to Longping Wen, Jiabin Li or Chen Zhu.

Ethics declarations

Ethics approval and consent to participate

All animal experiments were approved by the Animal Ethics Committee of Guangdong Provincial People’s Hospital (Approval No. KY-Q-2022–197-01).

Consent for publication

All authors agree to be published.

Competing interests

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1: Fig. S1.

Stability of Rp@Al on days 0, 3, and 7. Fig. S2. The preparation mechanism of Rp@Al. Fig. S3. Statistical analysis of scanning electron microscopy (SEM) images of Rp showing its diameter distribution. Fig. S4. Representative image of a growing Rp culture. Fig. S5. Time-lapse images showing the photothermal conversion of PBS, Rp, and Rp@Al. Fig. S6. Time-lapse images showing the photothermal conversion of PBS and different concentrations of Rp@Al. Fig. S7. Time-lapse images showing the photothermal conversion of Rp@Al using an 808-nm laser. Fig. S8. Levels of reactive oxygen species in methicillin-resistant Staphylococcus aureus (MRSA) after different treatment. Fig. S9. Temperature monitoring of the abscess site in mice under 808 nm laser irradiation. Fig. S10. Quantitative analysis showing collagen deposition levels in different treatment groups. Fig. S11. Representative flow scatter plot showing the percentage of CD4+ T cells in total leukocytes. Fig. S12. Comparative analysis of the proportion of memory B cells in mice from different treatment groups. Fig. S13. Time-lapse images showing the abscess recovery in treatment groups after second subcutaneous injection of MRSA. Fig. S14. The abscess recovery in different treatment groups after a second subcutaneous infection of MRSA. Fig. S15. Weight of the mice before intravenous re-infection with MRSA. Table S1. Summary of the photothermal conversion efficiency (η) of some photothermal agents that have been reported. Table S2. Summary of the pros and cons for different nanomaterials for antibacterial applications.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xu, Y., Wu, Y., Hu, Y. et al. Bacteria-based multiplex system eradicates recurrent infections with drug-resistant bacteria via photothermal killing and protective immunity elicitation. Biomater Res 27, 27 (2023). https://doi.org/10.1186/s40824-023-00363-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s40824-023-00363-0

Keywords

  • Photosynthetic bacteria
  • Aluminum adjuvant
  • Rp@Al
  • Photothermal therapy
  • Protective antimicrobial immunity
  • Recurrent drug-resistant bacterial infections

Biomaterials Research

ISSN: 2055-7124

Contact us